FDA Glutathione Injection Recall 2026: Endotoxin Contamination, Affected Lots and What Patients Should Know

The FDA glutathione injection recall 2026 has become an urgent patient-safety concern after two US compounding pharmacies voluntarily recalled glutathione 200 mg/mL multi-dose vials because testing identified elevated bacterial endotoxin levels. Four affected lots were named across two separate recall announcements published by the US Food and Drug Administration during August 2026.[1,2]

The latest announcement, published by the FDA on August 20, 2026, covers one lot produced by Optimal Balance Pharmacy. It followed an August 5 announcement involving three lots compounded by Victory Medical Center Pharmacy. Patients have reported fever, chills, severe headache, nausea, vomiting, body pain, rapid heartbeat, blood-pressure changes, injection-site reactions and symptoms resembling an allergic reaction.[1,2]

This is not merely a packaging or labelling issue. The recall notices warn that injectable products containing excessive endotoxin may cause severe inflammation, low blood pressure, anaphylactic shock and potentially death.[1,2]

Urgent safety note: Anyone who develops difficulty breathing, swelling of the face or tongue, fainting, confusion, severe weakness, chest tightness or rapidly worsening symptoms after receiving a glutathione injection should call the local emergency service immediately. Do not attempt to manage these symptoms with a home detoxification programme, fasting, purgation or herbal medicine.

Did the FDA itself recall the glutathione injections?

The commonly searched phrase “FDA glutathione injection recall” requires one important clarification. The affected compounding pharmacies initiated voluntary recalls, and the FDA published their company announcements as a public service. The FDA pages explicitly state that publication of an announcement does not represent endorsement of the company or product.[1,2]

Both recalls extend to the patient level, meaning patients who possess the affected vials must take action rather than waiting for a clinic, distributor or pharmacy to remove the product.

Which glutathione injection lots have been recalled?

Patients should check the pharmacy name, concentration, vial size, lot number and expiration date printed on the label. The FDA announcements identify the following products.

The latest Optimal Balance recall therefore concerns one specific lot, while the earlier VMC recall concerns three lots. The listed expiration date of August 27, 2026 applies to the three VMC lots.[1,2]

A patient should not judge the vial by whether the liquid looks clear, smells normal or has been stored correctly. The recall is based on laboratory findings, and the affected product must be identified from the label and lot number.

When the label is missing, unreadable or incomplete, the injection should not be used until the dispensing pharmacy has confirmed the product’s identity and recall status.

What should patients do with a recalled glutathione vial?

Patients who possess an affected vial should stop using it immediately and place it in quarantine. In practical terms, this means keeping the vial sealed, clearly separated from other medicines and unavailable for accidental administration while awaiting return or disposal instructions from the pharmacy.

Optimal Balance Pharmacy can be contacted at (218) 919-2964 between 9:00 a.m. and 5:00 p.m. Central Time, Monday through Friday. Victory Medical Center Pharmacy can be contacted at (512) 279-0985. Its FDA announcement lists extended weekday and weekend hours.[1,2]

Patients should also notify the clinician who prescribed or administered the injection. The pharmacy can arrange product retrieval and reimbursement, but it cannot replace a medical assessment when symptoms have occurred.

Difficulty breathing, facial or tongue swelling, fainting and loss of consciousness can indicate anaphylaxis or another life-threatening systemic reaction. Fever, shivering, confusion, a weak pulse, shortness of breath and extreme discomfort can also occur in sepsis. Both situations require rapid assessment rather than observation at home.[6,7]

What is bacterial endotoxin?

Bacterial endotoxin is a heat-stable lipopolysaccharide associated with the outer membrane of certain Gram-negative bacteria. It may be released when bacterial cells are disrupted. When an excessive amount enters the body through an injectable product, it can trigger an intense inflammatory response.[5]

The possible consequences include fever, chills, headache, muscle pain, nausea, vomiting, low blood pressure, circulatory shock and death. Because endotoxin is heat-stable, ordinary assumptions about heating or a product appearing clean do not establish that an injectable solution is safe.[3,5]

Elevated endotoxin does not automatically prove that living bacteria entered the bloodstream. Endotoxin is a bacterial component rather than a living organism. However, the resulting illness can resemble infection, sepsis or anaphylaxis, and symptoms alone cannot reliably distinguish these conditions. Medical evaluation is therefore essential.

What adverse events have been reported in the 2026 recalls?

Optimal Balance Pharmacy reported adverse events including fever, chills, severe headache, nausea, vomiting, pain and symptoms consistent with an allergic reaction. Its risk statement warns of fever, hypotension, inflammatory reactions, anaphylactic shock and death.[1]

Victory Medical Center Pharmacy reported fever, chills, severe headache, nausea, vomiting, tachycardia, blood-pressure changes, body aches and injection-site reactions. Its announcement carries the same warning about potentially serious inflammatory and circulatory consequences.[2]

These reported events do not mean that every exposed patient will become critically ill. They do mean that a recent glutathione injection should be disclosed immediately when a patient develops an otherwise unexplained acute illness.

This is not the first FDA warning involving glutathione and endotoxin

In 2019, the FDA investigated adverse reactions among seven patients who had received compounded intravenous glutathione. Within minutes, patients reportedly developed symptoms including nausea, vomiting, lightheadedness, chills and body aches. One experienced low blood pressure and breathing difficulty and was transferred to a hospital.[3]

The FDA received a separate report involving another patient who developed sudden chills, fever and shaking after a glutathione infusion and was admitted to hospital for a possible bloodstream infection. FDA laboratory testing found excessive bacterial endotoxin in all collected glutathione ingredient samples, with some findings reaching five times the calculated appropriate limit.[3]

The 2019 investigation also found that the raw glutathione ingredient had been intended for dietary-supplement use rather than sterile injectable manufacturing. This history demonstrates why an ingredient suitable for swallowing cannot automatically be considered suitable for injection.

What if the injection was received several days ago and the patient feels well?

Feeling well is reassuring, but it is not a reason to continue using a recalled lot.

The patient should stop all further doses, photograph the vial label, record the lot and expiration date, and contact both the dispensing pharmacy and prescribing clinician. The clinician can consider when the exposure occurred, whether any symptoms developed, the administered dose, relevant medical conditions and whether observation or testing is necessary.

Routine emergency testing may not be required for every asymptomatic person. Conversely, a person with symptoms should not be reassured merely because the vial was used several hours or days earlier. The appropriate response depends on the clinical condition rather than a fixed home-monitoring period.

What might doctors evaluate after a suspected reaction?

A clinician may assess temperature, heart rate, blood pressure, oxygen level, breathing, hydration, mental status and the injection site. Additional investigations can be selected according to symptoms and may include blood counts, kidney and liver function, inflammatory markers, lactate or blood cultures when infection or organ involvement is suspected.

Not every patient requires every test. The purpose of medical evaluation is to identify circulatory instability, severe inflammation, allergy-like reactions, infection or organ dysfunction early enough to intervene. The CDC advises immediate evaluation and treatment when sepsis is suspected.[6]

Patients should take the vial, packaging or a clear photograph of the label to the healthcare facility when this can be done safely. The product should not be reopened or transported in a manner that could expose another person to an accidental injection.

Are all glutathione injections recalled?

No. The August 2026 announcements identify particular compounded products and lot numbers. They do not state that every glutathione tablet, topical product or injection from every manufacturer is recalled.[1,2]

Nevertheless, a patient should not use a different glutathione injection simply because its lot number is absent from these notices. The new product still requires an appropriate medical indication, a traceable prescription, a licensed source, proper sterile compounding and a clear understanding of its expected benefits and risks.

Patients receiving glutathione through wellness clinics, anti-ageing centres, aesthetic practices or online providers should ask for the original pharmacy label. A handwritten clinic label without the compounder’s name, lot number, strength and expiration date makes product verification considerably more difficult.

Why does the word “compounded” matter?

A compounded medicine is prepared for a specific clinical need when an appropriate FDA-approved medicine cannot meet that patient’s requirements. Legitimate compounding can be valuable, such as when a patient needs a different dosage form or must avoid a particular ingredient.[4]

However, compounded drugs are not FDA-approved. The FDA does not verify their safety, effectiveness or quality through the standard premarket approval process. The agency warns that poor compounding practices can produce contamination, an excessive or insufficient amount of an active ingredient, serious injury or death.[4]

The FDA page publishing the Optimal Balance announcement reproduces the company’s description of the intended uses of its product. That wording should not be interpreted as an FDA-validated therapeutic claim because the same page states that the FDA does not endorse the company or product.[1]

Is intravenous glutathione proven for skin lightening or “detox”?

Glutathione is a naturally produced intracellular antioxidant involved in cellular redox balance. That biological role does not automatically establish that repeated high-dose intravenous glutathione provides a proven cosmetic, anti-ageing, immunity-enhancing or general “detoxification” benefit.

A 2016 clinical review found no adequate studies of intravenous glutathione for skin lightening and no evidence establishing the safety of chronic intravenous use.[8] A 2019 systematic review located four small clinical studies of skin-related effects, but those studies evaluated oral or topical glutathione rather than intravenous treatment. The reviewers concluded that the overall evidence for skin whitening remained inconclusive because of inconsistent findings and study-quality limitations.[9]

A patient considering intravenous glutathione for pigmentation should first obtain a dermatological diagnosis. Melasma, post-inflammatory pigmentation, medication-related changes, hormonal conditions, sun exposure and other disorders do not all respond to the same treatment. Treating the underlying driver is more rational than repeatedly suppressing its visible manifestation.

The same principle applies when glutathione is promoted for fatigue or liver “detox.” Persistent fatigue may be associated with anaemia, thyroid disease, sleep disorders, nutritional deficiencies, metabolic illness, chronic infection, medication effects or psychological stress. Liver disease also requires diagnosis rather than a generic infusion.

What should patients in the USA, UK, Singapore, Canada and Australia know?

The two FDA announcements list distribution within US states and do not report confirmed commercial distribution in the UK, Singapore, Canada or Australia.[1,2] Nevertheless, people who purchased a US-compounded vial online, obtained it while travelling or received it through a clinic that imports products should check the pharmacy and lot number as a precaution.

In the United States, suspected adverse reactions and quality problems can be reported through FDA MedWatch at:

https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program

In the United Kingdom, patients and healthcare professionals can report medicine reactions or defective products through the MHRA Yellow Card scheme at:

https://yellowcard.mhra.gov.uk

The MHRA confirms that patients can report suspected medicine problems even when causality has not been proven. (GOV.UK)

In Singapore, adverse events associated with health products can be reported to the Health Sciences Authority at:

https://www.hsa.gov.sg/adverse-events

The HSA encourages reporting as soon as an adverse event becomes known. (Health Sciences Authority)

In Canada, patients can use Health Canada’s MedEffect reporting service at:

https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html

Health Canada advises reporting suspected reactions even when the person is unsure that the product caused the problem. (Canada)

In Australia, consumers can report medicine-related adverse events through the Therapeutic Goods Administration at:

https://www.tga.gov.au/safety/report-problem/report-adverse-event-or-safety-problem/reporting-adverse-events-consumers

The TGA also allows a doctor, nurse practitioner or pharmacist to assist with reporting. (Therapeutic Goods Administration (TGA))

Reporting to a regulator does not replace emergency treatment or a direct consultation with the prescribing clinician.

Can Ayurveda help after a glutathione injection recall?

Ayurveda should not be presented as an emergency antidote to bacterial endotoxin. No Ayurvedic herb, Rasayana, drink, fasting protocol or Panchakarma procedure can be relied upon to neutralize an acute endotoxin reaction, reverse shock or manage anaphylaxis at home. Suspected severe reactions require modern emergency assessment and stabilization.

Ayurveda becomes relevant after the immediate danger has been excluded or treated. Its most valuable contribution is not to replace one antioxidant product with another. It is to investigate why the patient felt dependent on repeated glutathione injections and to build a more durable, individualized path toward recovery.

At Panaceayur, an appropriate assessment may examine the patient’s original concern, such as persistent pigmentation, fatigue, perceived poor immunity, metabolic dysfunction, digestive disturbance or liver-related symptoms. The physician can then evaluate diet, sleep, bowel function, stress, medications, laboratory findings and Agni, meaning the individual’s digestive and metabolic capacity.

The therapeutic goal is root-cause correction rather than repeatedly chasing a laboratory marker or temporary cosmetic effect. Depending on the diagnosis, the plan may include correction of dietary triggers, restoration of regular digestion and sleep, treatment of the underlying disorder and carefully selected Rasayana support. This approach can help the patient move toward sustained improvement while reducing reliance on inadequately justified wellness injections.

Rasayana therapy is described in Charaka Samhita, Chikitsa Sthana, Chapter 1, Rasayana Adhyaya. Its first subsection is the Abhaya-Amalakiya Rasayana Pada. Amalaki is also described in Bhavaprakasha Nighantu, Haritakyadi Varga, in the Amalaki section. These classical references support Amalaki’s traditional position within rejuvenative and restorative care, but they do not establish it as a treatment for injected endotoxin.

Modern research offers limited but relevant supporting evidence for the broader metabolic and antioxidant role of Amalaki. In a 12-week randomized, double-blind, placebo-controlled study involving 59 people with metabolic syndrome, a standardized Phyllanthus emblica extract improved measured endothelial function, glutathione levels, oxidative-stress markers, systemic inflammation and lipid parameters compared with placebo.[10] The trial supports further study of Amalaki as an adjunct in selected metabolic patients; it does not show that Amalaki treats endotoxin exposure or replaces emergency care.

Any Ayurvedic medicine should therefore be selected after the patient is medically stable and after reviewing concurrent medicines, kidney and liver status, metabolic health and the original diagnosis. Self-prescribing multiple “detox” herbs immediately after a suspected injection reaction may delay necessary care.

Patients interested in a physician-supervised, root-cause-oriented Ayurvedic plan can read Panaceayur’s overview of Amalaki Rasayana at:

Questions to ask before receiving another compounded injection

Before accepting another glutathione or wellness injection, ask the prescriber to state the medical indication in clear language. The expected benefit should be specific and measurable rather than limited to general phrases such as “detox,” “boosting immunity” or “anti-ageing.”

Ask which pharmacy compounded the product, whether it is operating under section 503A or registered as a 503B outsourcing facility, and which authority oversees it. Request the exact strength, ingredients, lot number, expiration date and storage requirements before administration.

Patients may also ask whether the finished lot underwent appropriate sterility and bacterial-endotoxin testing, whether the testing reflects the maximum intended intravenous dose, and what emergency arrangements are available if a systemic reaction develops. A certificate of analysis should be relevant to sterile injectable use rather than merely confirming that the raw ingredient is suitable for a dietary supplement.

Finally, ask whether an FDA-approved treatment, evidence-based dermatological therapy, nutritional correction or treatment of the underlying disease could address the same concern with less risk.

Final advice for patients

The FDA glutathione injection recall 2026 concerns four specific lots of compounded glutathione 200 mg/mL multi-dose vials produced by Optimal Balance Pharmacy and Victory Medical Center Pharmacy. Patients should stop using affected products, quarantine the vials, contact the pharmacy and notify their prescribing clinician.[1,2]

Symptoms such as fever, chills, severe headache, vomiting, body aches or injection-site inflammation require prompt medical advice. Breathing difficulty, facial or tongue swelling, fainting, confusion, severe weakness or signs of shock require immediate emergency care.

After the urgent safety issue has been resolved, patients can reconsider why the injections were being used. A properly diagnosed, individualized plan—including evidence-based conventional treatment and physician-supervised Ayurveda where appropriate—offers a safer route toward durable health improvement than repeated injections supported by uncertain cosmetic or wellness claims.

Frequently Asked Questions

Can patients detoxify endotoxin naturally at home?

No home detoxification method has been shown to neutralize an acute endotoxin reaction after injection. Symptomatic patients require medical assessment, and severe symptoms require emergency care.

Can Ayurveda be used after a reaction?

Ayurveda may be considered only after the patient has been medically evaluated and stabilized. It may support longer-term correction of the underlying pigmentation, metabolic, digestive or fatigue-related concern, but it does not replace emergency management of endotoxin exposure, sepsis or anaphylaxis.

References

1. U.S. Food and Drug Administration. (2026, August 20). Optimal Balance Pharmacy issues voluntary nationwide recall of certain lots of compounded glutathione 200 mg/mL multi-dose vials due to elevated endotoxin levels.
   https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/optimal-balance-pharmacy-issues-voluntary-nationwide-recall-certain-lots-compounded-glutathione-200
   Brief: Provides the latest affected lot, expiration date, distribution states, reported adverse events, pharmacy contact information and patient instructions.
2. U.S. Food and Drug Administration. (2026, August 5). Victory Medical Center Pharmacy issues voluntary nationwide recall of certain lots of compounded glutathione 200 mg/mL multi-dose vials due to elevated endotoxin levels.
   https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/victory-medical-center-pharmacy-issues-voluntary-nationwide-recall-certain-lots-compounded
   Brief: Identifies the three VMC lots, expiration date, distribution states, reported reactions and recall response.
3. U.S. Food and Drug Administration. (2019, June 7). FDA highlights concerns with using dietary ingredient glutathione to compound sterile injectables.
   https://www.fda.gov/drugs/human-drug-compounding/fda-highlights-concerns-using-dietary-ingredient-glutathione-compound-sterile-injectables
   Brief: Describes earlier hospitalizations and acute reactions linked to endotoxin-contaminated compounded glutathione and explains FDA laboratory findings.
4. U.S. Food and Drug Administration. (n.d.). Compounding and the FDA: Questions and answers.
   https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
   Brief: Explains why compounded medicines may be needed, why they are not FDA-approved and how poor compounding can cause contamination, injury or death.
5. U.S. Food and Drug Administration. (1991). Biotechnology inspection guide (11/91).
   https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-guides/biotechnology-inspection-guide-1191
   Brief: Defines endotoxin as a heat-stable lipopolysaccharide associated with Gram-negative bacteria and describes its potential to cause severe febrile reactions and death.
6. Centers for Disease Control and Prevention. (2026, August 17). About sepsis.
   https://www.cdc.gov/sepsis/about/index.html
   Brief: Describes warning signs such as fever, confusion, rapid heart rate, weak pulse and shortness of breath, and emphasizes immediate evaluation.
7. National Library of Medicine. (n.d.). Anaphylaxis. MedlinePlus Medical Encyclopedia.
   https://medlineplus.gov/ency/article/000844.htm
   Brief: Provides emergency warning signs including breathing difficulty, swallowing difficulty, dizziness, hives, facial or tongue swelling and unconsciousness.
8. Davids, L. M., van Wyk, J. C., & Khumalo, N. P. (2016). Intravenous glutathione for skin lightening: Inadequate safety data. South African Medical Journal, 106(8), 782–786.
   https://doi.org/10.7196/SAMJ.2016.v106i8.10878
   Brief: Found inadequate evidence for intravenous glutathione as a skin-lightening treatment and no established safety data for chronic intravenous use.
9. Dilokthornsakul, W., Dhippayom, T., & Dilokthornsakul, P. (2019). The clinical effect of glutathione on skin color and other related skin conditions: A systematic review. Journal of Cosmetic Dermatology, 18(3), 728–737.
   https://doi.org/10.1111/jocd.12910
   Brief: Reviewed four oral or topical studies and concluded that evidence for skin-whitening effects remained inconclusive because of inconsistent results and methodological limitations.
10. Usharani, P., Merugu, P. L., & Nutalapati, C. (2019). Evaluation of the effects of a standardized aqueous extract of Phyllanthus emblica fruits on endothelial dysfunction, oxidative stress, systemic inflammation and lipid profile in subjects with metabolic syndrome: A randomised, double-blind, placebo-controlled clinical study. BMC Complementary and Alternative Medicine, 19, Article 97.
    https://doi.org/10.1186/s12906-019-2509-5
    Brief: A 12-week randomized study found improvement in selected endothelial, antioxidant, inflammatory and lipid markers with standardized Amalaki extract. It supports adjunctive metabolic research but does not establish treatment of endotoxin exposure.

Classical Ayurveda source locations

Charaka Samhita, Chikitsa Sthana, Chapter 1, Rasayana Adhyaya, particularly the Abhaya-Amalakiya Rasayana Pada.

https://www.carakasamhitaonline.com/index.php/Rasayana_Adhyaya

Bhavamishra, Bhavaprakasha Nighantu, Haritakyadi Varga, Amalaki section.